1Ney P, Pandita RK, Newgreen DT, et al. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo[J]. BJU Int, 2008,101(8) : 1036-1042.
2Malhotral B, Guanl Z, Wood N, et al. Pharmacokinetic profile of fesoterodine[J].Int J Clin Pharmacol Ther, 2008, 46 (11):556- 563.
3Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder[J]. 2007, 52(4) :1204-1212.
4Chapple, CR, Van Kerrebroeck PE, Junemamn KP,et al. Comparison of fesoterodine and toherodine in patients with overactive bladder [J]. BJU Int, 2008 Jul 21. Epub ahead of print.
5Kelleher C J, Tubaro A, Wang JT, et al. Impact of fesoterodine on quality of life: pooled data from two randomized trials[J]. BJU Int, 2008,102(1): 56-61.
6Nitti VW, Dmochowski R,Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome[J]. J Urol, 2007,178 ( 6 ) : 2488-2494.
